Seminars in Oncology
Volume 35 , Pages S34-S43 , June 2008

Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors

  • Joaquim Bellmunt

      Affiliations

    • University Hospital Del Mar, Barcelona, Spain.
    • Corresponding Author InformationAddress correspondence to Joaquim Bellmunt, MD, Medical Oncology Service, University Hospital del Mar, Paseo Maritimo 25-29, Barcelona 08003, Spain.
    • ,
  • Francois-Michel Delgado

      Affiliations

    • Institut de Recherche Pierre Fabre, Boulogne, France.
    • ,
  • Claude George

      Affiliations

    • Bristol-Myers Squibb, Princeton, NJ.

References 

  1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–265
  2. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005;5:65–71
  3. Fahy J, Duflos A, Ribet JP, et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc. 1997;119:8576–8577
  4. Fahy J. Modifications in the “upper” velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des. 2001;7:1181–1197
  5. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437–447
  6. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998;55:635–648
  7. Lobert S, Ingram JW, Correia JJ. The thermodynamics of vinca alkaloid-induced tubulin spirals formation. Biophys Chem. 2007;126:50–58
  8. Barret JM, Etievant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol. 2000;45:471–476
  9. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14:630–637
  10. Bennouna J, Campone M, Delord JP, Pinel MC. Vinflunine: A novel antitubulin agent in solid malignancies. Expert Opin Invest Drugs. 2005;14:1259–1267
  11. Johnson P, Geldart T, Fumoleau P, Pinel MC, Nguyen L, Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24:223–231
  12. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol. 2002;7:159–166
  13. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94:1395–1401
  14. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, De Marco S, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). [Abstract 15543] J Clin Oncol. 2007;25(18S):653s
  15. Petrylak DP, Vaughn DJ, Srinivas S, Pili R, Stadler W, Sternberg C, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). Eur J Cancer Suppl. 2007;5:309;(Abstr 4534)
  16. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506–513
  17. Galsky M, Sonpavde G, Hutson TE. Current management of bladder cancer. US Oncological Disease. 2006;6:62–66
  18. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004;9:617–632
  19. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: A new active drug for second-line treatment of advanced breast cancer (Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy). Br J Cancer. 2006;95:1161–1166
  20. Fumoleau P, Campone M, Vorobiof D, Casado M, Ruff P, Khoo Kei S, et al. Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. J Clin Oncol. 2004;22:329;(abstr 542)
  21. Campone M, Fumoleau P, Roche H, et al. A dose-finding and pharmacokinetic study of I.V. vinflunine (VFL) in combination with capecitabine (CAPE) as second line treatment of metastatic breast cancer (MBC). 2006;Proceedings of the San Antonio Breast Cancer Symposium; December 14; San Antonio, TX
  22. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536–542
  23. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  24. Paridaens R, Wildiers H, Dalenc F, Rixe O, Cadic V, Pinel M, et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J Clin Oncol. 2007;25:1020;(abstr 1058)
  25. Peacock NW, Spigel DR, Mainwaring PN, Thompson DS, Simons L, Rubin MS, et al. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer cancer. [abstract 1043] J Clin Oncol. 2007;28(18S):42s
  26. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006;52:155–163
  27. Kelly K, Crowley J, Bunn PAJ, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–3218
  28. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122–130
  29. Kumar A, Wakelee H. Second- and third-line treatments in non-small cell lung cancer. Curr Treat Options Oncol. 2006;7:37–49
  30. Bozcuk H, Dalmis B, Samur M, Ozdogan M, Artac M, Savas B. Quality of life in patients with advanced non-small cell lung cancer. Cancer Nurs. 2006;29:104–110
  31. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer. 2006;94:1383–1388
  32. Krzakowski M, Douillard J, Ramlau R, Jassem J, Szczesna A, Zatloukal P, et al. Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol. 2007;25:4278;(abstr 7511)
  33. Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O'Brien M, Kosmidis P, et al. Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer. 2006;94:1383–1388
  34. Ramlau R, Souquet P-J, Sun X, Lopez-Vivanco G, Afenjar K, Colin C, et al. Results of a phase I/II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2004;22:2723;(abstr 7110)
  35. Tourani J, Pinel M, Planchard D, Aslanis V, Gouva S, Robinet G. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results. [abstract 7271] J Clin Oncol. 2005;23(16S):688s
  36. Tourani J, Pinel M, Planchard D, Aslanis V, Gouva S, Robinet G, et al. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results. J Clin Oncol. 2005;23:(abstr 7271)
  37. Blackhall FH, Shepherd FA. Small cell lung cancer and targeted therapies. Curr Opin Oncol. 2007;19:103–108
  38. Murray N, Turrisi AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 2006;1:270–278
  39. MacCallum C, Gillenwater HH. Second-line treatment of small-cell lung cancer. Curr Oncol Rep. 2006;8:258–264
  40. Peyton JD, Spigel DR, Hainsworth JD, Yardley DA, Burris HA, Vazquez E, et al. Phase II trial of vinflunine in patients with relapsed small cell lung cancer. J Clin Oncol. 2007;25:(abstr 18091)
  41. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 2003;21:1550–1555
  42. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347–351
  43. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092
  44. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol. 2005;16:345–351
  45. Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E. Malignant mesothelioma (The Eastern Cooperative Oncology Group (ECOG) experience). Cancer. 1983;52:1981–1985
  46. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study. Invest New Drugs. 1988;6:223–226
  47. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol. 1990;27:239–242
  48. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18:3912–3917
  49. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556–1561
  50. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  51. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol. 2007;25:4751–4756
  52. Paule B, Saliba F, Gil-Delgado M, Puozzo C, Favrel S, Ravaud A, et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results. J Clin Oncol. 2007;15(18S):102s;(abstr 2423)

 Dr Bellmunt has no conflict of interest to declare. Dr Delgado is an employee of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine. Dr George is an employee of Bristol-Myers Squibb.

PII: S0093-7754(08)00021-3

doi: 10.1053/j.seminoncol.2008.01.008

Seminars in Oncology
Volume 35 , Pages S34-S43 , June 2008

Article Tools